---
title: Japan Patent Term Extension (PTE) Pharma Guide | EVORIX
description: "Japan Patent Term Extension (PTE) guide for pharmaceutical and agrochemical patents: eligibility, MHLW disposition link, calculation, and 5-year max term."
image: https://www.evorix.jp/hubfs/EVORIX-logo-rich.png
---

[Skip to content](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#main-content)

[![知的財産事務所エボリクス/EVORIX/大阪/特許・商標・意匠登](https://www.evorix.jp/hs-fs/hubfs/%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png?width=500&height=250&name=%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png)](https://www.evorix.jp/)

- [Services](https://www.evorix.jp/en/contents)
  
  Show submenu for Services 
  
    - [Patent Filing](https://www.evorix.jp/en/patent-service)
    - [Trademark Registration](https://www.evorix.jp/en/trademark-service)
    - [Design Registration](https://www.evorix.jp/en/design-service)
    - [Copyright](https://www.evorix.jp/en/copyright-service)
    - [Unfair Competition](https://www.evorix.jp/en/unfair-competition)
    - [Patent Attorney Advisor](https://www.evorix.jp/en/komon)
- [International Filing](https://www.evorix.jp/en/international)
  
  Show submenu for International Filing 
  
    - [PCT International Patent](https://www.evorix.jp/en/pct)
    - [Madrid Protocol Trademark](https://www.evorix.jp/en/madrid-protocol-trademark)
    - [Hague Design Application](https://www.evorix.jp/en/hague-design-application)
    - [Global Patent Systems](https://www.evorix.jp/patent-world)
    - [Global Trademark Systems](https://www.evorix.jp/trademark-world)
    - [Global Design Systems](https://www.evorix.jp/design-world)
- [Industries](https://www.evorix.jp/en/industries)
  
  Show submenu for Industries 
  
    - [For Startups](https://www.evorix.jp/en/startup)
    - [For Manufacturing](https://www.evorix.jp/en/manufacturing)
    - [For IT Companies](https://www.evorix.jp/it-ip-portal)
- [About Us](https://www.evorix.jp/en/about)
  
  Show submenu for About Us 
  
    - [Firm Overview](https://www.evorix.jp/en/about)
    - [Philosophy & Vision](https://www.evorix.jp/philosophy)
    - [Our Patent Attorneys](https://www.evorix.jp/en/staff)
    - [Locations](https://www.evorix.jp/en/access)
    - [Seminars & Lectures](https://www.evorix.jp/en/seminar)
    - [Careers](https://www.evorix.jp/en/recruit)
- [Resources](https://www.evorix.jp/en/blog)
  
  Show submenu for Resources 
  
    - [Blog](https://www.evorix.jp/en/blog)
    - [FAQ](https://www.evorix.jp/en/faq)
    - [IP Glossary](https://www.evorix.jp/en/glossary)
    - [Foreign Filing Subsidy Guide](https://www.evorix.jp/%E3%82%B8%E3%82%A7%E3%83%88%E3%83%AD%E5%A4%96%E5%9B%BD%E5%87%BA%E9%A1%98%E5%8A%A9%E6%88%90%E9%87%91%E3%81%AE%E3%81%94%E6%A1%88%E5%86%85)
    - [AI Draft × Patent Attorney Check](https://www.evorix.jp/ai-draft-patent-lp)
- [Contact](https://www.evorix.jp/en/inquiry)
  
  Show submenu for Contact 
  
    - [Consultation Process](https://www.evorix.jp/en/consultation)
    - [Inquiry Form](https://www.evorix.jp/en/inquiry)

Open main navigation

Close main navigation

- [Services](https://www.evorix.jp/en/contents)
  
  Show submenu for Services 
  
    - [Patent Filing](https://www.evorix.jp/en/patent-service)
    - [Trademark Registration](https://www.evorix.jp/en/trademark-service)
    - [Design Registration](https://www.evorix.jp/en/design-service)
    - [Copyright](https://www.evorix.jp/en/copyright-service)
    - [Unfair Competition](https://www.evorix.jp/en/unfair-competition)
    - [Patent Attorney Advisor](https://www.evorix.jp/en/komon)
- [International Filing](https://www.evorix.jp/en/international)
  
  Show submenu for International Filing 
  
    - [PCT International Patent](https://www.evorix.jp/en/pct)
    - [Madrid Protocol Trademark](https://www.evorix.jp/en/madrid-protocol-trademark)
    - [Hague Design Application](https://www.evorix.jp/en/hague-design-application)
    - [Global Patent Systems](https://www.evorix.jp/patent-world)
    - [Global Trademark Systems](https://www.evorix.jp/trademark-world)
    - [Global Design Systems](https://www.evorix.jp/design-world)
- [Industries](https://www.evorix.jp/en/industries)
  
  Show submenu for Industries 
  
    - [For Startups](https://www.evorix.jp/en/startup)
    - [For Manufacturing](https://www.evorix.jp/en/manufacturing)
    - [For IT Companies](https://www.evorix.jp/it-ip-portal)
- [About Us](https://www.evorix.jp/en/about)
  
  Show submenu for About Us 
  
    - [Firm Overview](https://www.evorix.jp/en/about)
    - [Philosophy & Vision](https://www.evorix.jp/philosophy)
    - [Our Patent Attorneys](https://www.evorix.jp/en/staff)
    - [Locations](https://www.evorix.jp/en/access)
    - [Seminars & Lectures](https://www.evorix.jp/en/seminar)
    - [Careers](https://www.evorix.jp/en/recruit)
- [Resources](https://www.evorix.jp/en/blog)
  
  Show submenu for Resources 
  
    - [Blog](https://www.evorix.jp/en/blog)
    - [FAQ](https://www.evorix.jp/en/faq)
    - [IP Glossary](https://www.evorix.jp/en/glossary)
    - [Foreign Filing Subsidy Guide](https://www.evorix.jp/%E3%82%B8%E3%82%A7%E3%83%88%E3%83%AD%E5%A4%96%E5%9B%BD%E5%87%BA%E9%A1%98%E5%8A%A9%E6%88%90%E9%87%91%E3%81%AE%E3%81%94%E6%A1%88%E5%86%85)
    - [AI Draft × Patent Attorney Check](https://www.evorix.jp/ai-draft-patent-lp)
- [Contact](https://www.evorix.jp/en/inquiry)
  
  Show submenu for Contact 
  
    - [Consultation Process](https://www.evorix.jp/en/consultation)
    - [Inquiry Form](https://www.evorix.jp/en/inquiry)
- [Contact](https://www.evorix.jp/en/inquiry)

[Contact](https://www.evorix.jp/en/inquiry)

 2026/05/24

# Japan Patent Term Extension (PTE) for Pharma: Foreign Counsel Guide

![Picture of Takefumi Sugiura – Japanese Patent Attorney](https://app.hubspot.com/settings/avatar/4ef5aa3d824852243e3f9a0ef7c7a511) [Takefumi Sugiura – Japanese Patent Attorney](https://www.evorix.jp/en/blog/author/takefumi-sugiura-japanese-patent-attorney)

Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma) [Twitter icon](https://twitter.com/intent/tweet?url=https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma) [envelope icon](mailto:?body=https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma)

![Japan Patent Term Extension (PTE) for Pharma: Foreign Counsel Guide](https://www.evorix.jp/hubfs/EVORIX-logo-rich.png)

For foreign counsel handling pharmaceutical or agrochemical patents in Japan, Patent Term Extension (PTE) can extend the effective patent life by up to 5 years — often the difference between a commercially viable product launch and a generic-eroded portfolio. This guide covers PTE eligibility, calculation, and the 3-month filing deadline that catches many foreign filers off guard.

Table of Contents

1. [Japan PTE Overview](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#overview)
2. [Eligibility Requirements](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#eligibility)
3. [PTE Term Calculation](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#calculation)
4. [PTE Application Process](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#application)
5. [Scope of Extended Right](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#scope)
6. [Strategic Considerations](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#strategy)
7. [FAQ](https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma#faq)

## Japan PTE Overview

Japan Patent Term Extension is governed by Articles 67-2 through 67-9 of the Patent Act. The system was introduced in 1988 to harmonize with US PTE (35 U.S.C. § 156) and EU SPC (Supplementary Protection Certificate). However, the Japanese system has unique features that differ from both.

**5-Year Maximum:** PTE extends the patent term by up to 5 years, capped at the actual non-working period due to regulatory review. The total extended term cannot exceed the original term + 5 years.

## Eligibility Requirements

Four conditions must be met:

1. **Patented product requires regulatory approval:** Pharmaceuticals (MHLW), agrochemicals (MAFF), or veterinary drugs.
2. **Approval was actually required:** Cannot extend for products that did not need approval.
3. **Non-working period was 2+ years:** The patent could not be worked for at least 2 years due to regulatory review.
4. **PTE application filed within 3 months of approval:** Strict deadline, no extension.

## PTE Term Calculation

The PTE term equals the regulatory non-working period, calculated as:

**Formula:** PTE Term = Approval Date − max(Patent Grant Date, Clinical Trial Start Date) − Applicant's Delay Days

Practical examples:

| Scenario | Patent Grant | Trial Start | Approval | PTE Term |
| --- | --- | --- | --- | --- |
| Pharma A | 2015-06-01 | 2016-09-15 | 2024-04-01 | 5 years (max) |
| Pharma B | 2020-01-10 | 2019-12-01 | 2024-02-15 | 4 years 1 month |
| Agrochem C | 2018-03-20 | 2020-05-10 | 2023-08-01 | 3 years 2 months |

## PTE Application Process

1. **Regulatory approval issued:** MHLW issues marketing authorization for the pharmaceutical product.
2. **Calculate non-working period:** Determine the precise dates of trial commencement and approval.
3. **File PTE application within 3 months:** Submit Form 67 with regulatory documents.
4. **JPO substantive examination:** Examiner verifies eligibility, dates, and product-patent correspondence (8-14 months typical).
5. **Office actions if applicable:** Respond within 3 months; common issues include claim-product matching and trial start date evidence.
6. **Extension registered:** Recorded against the original patent.

## Scope of Extended Right

Critical Supreme Court precedent (Pacif Capsule case, 2017) clarified the PTE scope. The extended right covers:

- **The specific product approved:** Identical active ingredient, dosage form, indication.
- **Closely similar products:** Variations not requiring separate approval (e.g., minor formulation changes).
- **NOT covered:** Different indications, different active ingredients, substantially different dosage forms.

**Multiple PTE Strategy:** If your patent supports multiple products (e.g., different dosage strengths, different indications approved at different times), file separate PTE applications for each. This maximizes coverage but requires precise tracking.

## Strategic Considerations

### When to Engage Japanese Counsel

- **1 year before NDA filing in Japan:** Confirm patent-product correspondence and PTE strategy.
- **At MHLW dossier submission:** Begin assembling PTE evidence (trial start documentation).
- **At PMDA Pre-Application Consultation:** Coordinate approval timing with PTE filing window.
- **Immediately upon approval:** 3-month clock starts; do not delay.

### Common Foreign Counsel Mistakes

- Filing PTE in 3rd or 4th month after approval (deadline missed)
- Not coordinating with regulatory affairs team for approval date confirmation
- Failing to identify all eligible products under one patent
- Missing the related "extension request" for closely linked patents (formulation patents, polymorphs)
- Incorrect calculation of trial start date (use the first authorized trial in Japan, not earlier foreign trials)

### PTE + Generic Defense

PTE-extended patents are heavily attacked by generic challengers. Defensive strategy:

- File invalidation pre-emption: ensure prior art is fully addressed in original prosecution
- Polymorphic and formulation patents extend de facto exclusivity beyond PTE
- Pediatric extension is NOT available in Japan (unlike US/EU)
- Data exclusivity (8 years for new drugs) operates separately from patent term

Need Japan IP Support?

Quote within 24 hours · English/Chinese/Korean/German/French/Spanish/Portuguese

[Request a Quote](https://www.evorix.jp/en/inquiry)[Service Overview](https://www.evorix.jp/en/foreign-counsel)

## Frequently Asked Questions

Q. What is Japan Patent Term Extension (PTE)?

A. PTE (特許権の存続期間の延長) compensates for regulatory delays. If a patented pharmaceutical or agrochemical product cannot be commercially worked due to MHLW (PMDA) or MAFF approval requirements, the patent term can be extended up to 5 years beyond the standard 20-year term.

Q. Which patents are eligible for PTE in Japan?

A. Patents covering: (1) pharmaceutical products requiring approval under the Pharmaceutical Affairs Act, (2) agrochemicals requiring approval under the Agricultural Chemicals Regulation Act. Medical devices and biologics requiring regulatory approval are also eligible.

Q. How is the PTE term calculated?

A. The PTE equals the period the patent could not be worked due to regulatory disposition, capped at 5 years. The "non-working period" starts from the later of patent grant date or clinical trial start, and ends on the date of MHLW marketing approval.

Q. When must I file the PTE application?

A. Within 3 months of the regulatory approval (MHLW marketing authorization). Late filing cannot be remedied. Missing this deadline means losing the entire PTE benefit.

Q. Does PTE cover multiple products?

A. One patent can support multiple PTE applications if multiple products are approved. Each product requires a separate PTE filing with the corresponding approval data. This is critical for platform patents covering multiple commercial products.

## Related Resources

[Pharma Industry LP Specialized pharma IP services](https://www.evorix.jp/en/pharma-foreign-counsel)[Foreign Counsel Hub Complete Japan IP overview](https://www.evorix.jp/en/foreign-counsel)[Get a Quote PTE filing cost estimate](https://www.evorix.jp/en/quote)

## Related posts

[![](https://www.evorix.jp/hs-fs/hubfs/EVORIX-logo-rich.png?height=200&name=EVORIX-logo-rich.png)](https://www.evorix.jp/en/blog/japan-patent-translation-quality-cost)

## [Japan Patent Translation: Quality vs Cost for Foreign Counsel](https://www.evorix.jp/en/blog/japan-patent-translation-quality-cost)

![Picture of Takefumi Sugiura – Japanese Patent Attorney](https://app.hubspot.com/settings/avatar/4ef5aa3d824852243e3f9a0ef7c7a511) [Takefumi Sugiura – Japanese Patent Attorney](https://www.evorix.jp/en/blog/author/takefumi-sugiura-japanese-patent-attorney) 

 2026/05/24

Patent translation quality directly determines the scope of protection you receive in Japan. A...

[Read more](https://www.evorix.jp/en/blog/japan-patent-translation-quality-cost)

[![](https://www.evorix.jp/hs-fs/hubfs/EVORIX-logo-rich.png?height=200&name=EVORIX-logo-rich.png)](https://www.evorix.jp/en/blog/japan-patent-annuity-service-guide)

## [Japan Patent Annuity Service: Complete Guide for Foreign Counsel](https://www.evorix.jp/en/blog/japan-patent-annuity-service-guide)

![Picture of Takefumi Sugiura – Japanese Patent Attorney](https://app.hubspot.com/settings/avatar/4ef5aa3d824852243e3f9a0ef7c7a511) [Takefumi Sugiura – Japanese Patent Attorney](https://www.evorix.jp/en/blog/author/takefumi-sugiura-japanese-patent-attorney) 

 2026/05/24

For foreign IP counsel managing Japanese patent portfolios, annuity (maintenance fee) management is...

[Read more](https://www.evorix.jp/en/blog/japan-patent-annuity-service-guide)

[![](https://www.evorix.jp/hs-fs/hubfs/EVORIX-logo-rich.png?height=200&name=EVORIX-logo-rich.png)](https://www.evorix.jp/en/blog/japan-utility-model-foreign-counsel-guide)

## [Japan Utility Model: When Should Foreign Counsel File?](https://www.evorix.jp/en/blog/japan-utility-model-foreign-counsel-guide)

![Picture of Takefumi Sugiura – Japanese Patent Attorney](https://app.hubspot.com/settings/avatar/4ef5aa3d824852243e3f9a0ef7c7a511) [Takefumi Sugiura – Japanese Patent Attorney](https://www.evorix.jp/en/blog/author/takefumi-sugiura-japanese-patent-attorney) 

 2026/05/24

Japanese utility models (実用新案) offer foreign counsel a fast, low-cost registration option for...

[Read more](https://www.evorix.jp/en/blog/japan-utility-model-foreign-counsel-guide)

---

[![知的財産事務所エボリクス/EVORIX/大阪/特許・商標・意匠登](https://www.evorix.jp/hs-fs/hubfs/%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png?width=500&height=250&name=%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png "知的財産事務所エボリクス/EVORIX/大阪/特許・商標・意匠登")](https://www.evorix.jp)

Intellectual Property Law Firm EVORIX

 

4th Floor, Qus-Hiranomachi Building,  
3-1-2 Hiranomachi, Chuo-Ku, Osaka-shi,  
Osaka 541-0046 Japan

Mail: [contact@evorix.jp](mailto:contact@evorix.jp)

TEL: +81-6-7777-1884

- [Hague International Design Application](https://www.evorix.jp/hague-design-application)
- [Madrid Protocol International Trademark Application](https://www.evorix.jp/madrid-protocol-trademark)
- [Amazon IP Infringement Support](https://www.evorix.jp/amazon-infringement)

- [About Us](https://www.evorix.jp/about)
- [Our Attorneys](https://www.evorix.jp/staff)
- [Services](https://www.evorix.jp/contents)
- [Consultation Process](https://www.evorix.jp/consultation)
- [Blog](https://www.evorix.jp/blog)
- [Careers](https://www.evorix.jp/recruit)
- [Trademark Portfolio](https://www.evorix.jp/trademark-list)
- [Privacy Policy](https://www.evorix.jp/hubfs/%E8%B3%87%E6%96%99/HP-%E3%83%97%E3%83%A9%E3%82%A4%E3%83%90%E3%82%B7%E3%83%BC%E3%83%9D%E3%83%AA%E3%82%B7%E3%83%BC.pdf)
- [Contact](https://www.evorix.jp/inquiry)

---

 

Copyright © 2026, Intellectual Property Law Firm EVORIX® All rights reserved. 

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Takefumi Sugiura – Japanese Patent Attorney",
    "url" : "https://www.evorix.jp/en/blog/author/takefumi-sugiura-japanese-patent-attorney"
  },
  "dateModified" : "2026-05-24T01:12:32.358Z",
  "datePublished" : "2026-05-24T01:12:32.000Z",
  "headline" : "Japan Patent Term Extension (PTE) Pharma Guide | EVORIX",
  "image" : [ "https://www.evorix.jp/hubfs/EVORIX-logo-rich.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.evorix.jp/hubfs/%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png"
    },
    "name" : "知的財産事務所エボリクス"
  }
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "affiliation" : "EVORIX Intellectual Property Firm",
    "jobTitle" : "Patent Attorney",
    "name" : "Takefumi Sugiura"
  },
  "datePublished" : "2026-05-24",
  "description" : "Japan Patent Term Extension (PTE) guide for pharmaceutical and agrochemical patents: eligibility, MHLW disposition link, calculation, and 5-year max term.",
  "headline" : "Japan Patent Term Extension (PTE) for Pharma: Foreign Counsel Guide",
  "image" : "https://www.evorix.jp/hubfs/EVORIX-logo-rich.png",
  "mainEntityOfPage" : "https://www.evorix.jp/en/blog/japan-patent-term-extension-pte-pharma",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.evorix.jp/hubfs/EVORIX-logo-rich.png"
    },
    "name" : "EVORIX"
  }
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "PTE (特許権の存続期間の延長) compensates for regulatory delays. If a patented pharmaceutical or agrochemical product cannot be commercially worked due to MHLW (PMDA) or MAFF approval requirements, the patent term can be extended up to 5 years beyond the standard 20-year term."
    },
    "name" : "What is Japan Patent Term Extension (PTE)?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Patents covering: (1) pharmaceutical products requiring approval under the Pharmaceutical Affairs Act, (2) agrochemicals requiring approval under the Agricultural Chemicals Regulation Act. Medical devices and biologics requiring regulatory approval are also eligible."
    },
    "name" : "Which patents are eligible for PTE in Japan?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "The PTE equals the period the patent could not be worked due to regulatory disposition, capped at 5 years. The \"non-working period\" starts from the later of patent grant date or clinical trial start, and ends on the date of MHLW marketing approval."
    },
    "name" : "How is the PTE term calculated?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Within 3 months of the regulatory approval (MHLW marketing authorization). Late filing cannot be remedied. Missing this deadline means losing the entire PTE benefit."
    },
    "name" : "When must I file the PTE application?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "One patent can support multiple PTE applications if multiple products are approved. Each product requires a separate PTE filing with the corresponding approval data. This is critical for platform patents covering multiple commercial products."
    },
    "name" : "Does PTE cover multiple products?"
  } ]
}
```